Oral Oncology, Journal Year: 2024, Volume and Issue: 156, P. 106930 - 106930
Published: July 3, 2024
Language: Английский
Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 174 - 174
Published: Jan. 8, 2025
The incidence and mortality of anal squamous cell carcinoma (ASCC) are rising, with greater than 80% cases linked to human papillomavirus (HPV), primarily HPV16. Post-treatment surveillance can be challenging due the limitations anoscopy, digital rectal exam (DARE), imaging. Plasma tumor tissue modified viral (TTMV)-HPV DNA has shown strong sensitivity, specificity, predictive value in detecting recurrence HPV-driven oropharyngeal cancer. Here, we investigate ability TTMV-HPV for early detection ASCC. This retrospective clinical case series included 117 patients ASCC across 7 U.S. centers, monitored during routine care between March 2020 June 2024. Physician-reported data biomarker testing were combined create a comprehensive, longitudinal dataset evaluating test performance metrics. Patients had median age 63 years post-diagnosis follow-up 19 months. HPV status was confirmed by (52%) or p16 immunohistochemistry (39%). Of those tested pretreatment, 85% positive result. clearance within three months post-treatment associated significantly better recurrence-free survival. per-patient (PPV), negative (NPV) 82.8%, 98.4%, 96.0%, 92.5%. 24 documented test, first evidence 14 (58.3%), lead time 59 days (range: 10-536). accurately resolved 94.3% indeterminate findings. provides sensitive specific approach recurrent resolving
Language: Английский
Citations
0
JAMA Otolaryngology–Head & Neck Surgery, Journal Year: 2025, Volume and Issue: unknown
Published: March 13, 2025
Importance Despite the favorable prognosis for HPV−positive oropharyngeal squamous cell carcinoma (HPV + OPSCC), efforts to de-escalate treatment intensity, while maintaining low recurrence and mortality rates, have proven challenging. Identifying appropriate prognostic factors remains elusive; however, association of pretreatment circulating tumor tissue viral−modified HPV (TTMV-HPV) DNA level with known characteristics disease burden—clinical staging, imaging, aggressive histopathologic features surgical specimen—may offer insights that could shift paradigms OPSCC. Objective To investigate TTMV-HPV levels clinical, radiologic, histopathologic, outcome metrics in patients Design, Setting, Participants This cohort study OPSCC positive test results fragment used data from a single tertiary center April 2020 September 2023. fragments were categorized into 3 cohorts: (≤99 fragments/mL), moderate (100-999/mL), high (≥1000/mL). Main Outcomes Measures Association clinical (cT) nodal (cN) staging level. Secondary outcomes included between emission tomography−computed tomography (PET-CT) as well specimen. The receiving adjuvant therapy was also analyzed. Recurrence-free survival disease-specific assessed. Results population 203 (mean [SD] age, 62 [10] years; 24 [12%] females 179 males [88%]), 58 (29%) whom low, 73 (36%) moderate, 72 (35%) fragment-level cohort. Compared cT0/1 stage, those cT2 stage cT3/4 had increased odds higher levels, adjusted ratios (aORs) 2.33 (95% CI, 1.24-4.46) 2.51 1.17-5.46), respectively. cN0 cN1 cN2/3 aORs 4.26 1.82-10.34) 3.64 1.46-9.36), In analysis PET-CT characteristics, total primary plus volume associated an aOR 1.04 1.02-1.07). Among 94 patients, no significant found lymphovascular invasion, perineural pathologic T number nodes, or extranodal extension on pathological No differences recurrence-free found. Conclusion Relevance more advanced aggregate cervical results. Future studies are needed explore how may influence decisions.
Language: Английский
Citations
0
Oral Oncology, Journal Year: 2025, Volume and Issue: 164, P. 107262 - 107262
Published: April 1, 2025
Language: Английский
Citations
0
Oral Oncology, Journal Year: 2024, Volume and Issue: 156, P. 106930 - 106930
Published: July 3, 2024
Language: Английский
Citations
0